

Serial No.: 09/661,696
Filed September 14, 2000

REMARKS

Claims 7, 9-11 and 26-52 are pending following entry of this Amendment.

Applicants reserve the right to pursue the subject matter of cancelled claims 1-6, 8 and 12-25 in a continuation application.

REJECTION OF THE CLAIMS UNDER 35 U.S.C. 102

The rejection of claims 1-5, 7-12 and 14-21 under 102 (b) as anticipated by WO 98/24883 is rendered moot by the cancellation of these claims in the present Amendment.


REJECTION OF THE CLAIMS UNDER 35 U.S.C. 103

The rejection of claims 1-5, 7-12 and 14-25 under section 103 as obvious over WO 98/24883 taken with Wang [J.Parenteral Science and Technology (1988) 42:4-26] is rendered moot by the cancellation of these claims in the present Amendment.

In view of the above amendments, the present application is believed to be in condition for allowance and early and favorable consideration by the Examiner is respectfully solicited.

Respectfully submitted,

Date: August 11, 2004


Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application

23650

PATENT TRADEMARK OFFICE